# KaliVir Immunotherapeutics

Source: https://onco.cc/companies/kalivir-immunotherapeutics/  
OnCo record `kalivir-immunotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KaliVir Immunotherapeutics engineers viruses that infect and break open cancer cells while stirring an immune response. Its lead virus, VET3-TGI, is in an early trial in advanced solid tumours, alone and with the immunotherapy atezolizumab.

## Summary

KaliVir Immunotherapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania; its website says its chief scientific officer co-founded it in 2019. Its Vaccinia Enhanced Template (VET) platform engineers oncolytic vaccinia viruses for systemic delivery and transgene expression in tumours. VET3-TGI expresses IL-12 and a TGF beta inhibitor and is given by intratumoural injection or intravenous infusion, alone or with atezolizumab, in the phase 1/1b STEALTH-001 trial (NCT06444815). In August 2026 the company closed a 14 million US dollar Series A extension led by Company K Partners with SV Investment and Flexus Partners, bringing the Series A to 25 million dollars. Its first registered cancer trial, NCT06444815, was posted on ClinicalTrials.gov in June 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Pittsburgh, PA
- Type: biotech
- Website: https://kalivir.com/

## Notes

- Founding year from the company website's statement that its CSO co-founded KaliVir in 2019.
- Press release of 19 August 2026 and company website read on 29 October 2026.

## Sources

- Official website: https://kalivir.com/
- ClinicalTrials.gov: phase 1/1b STEALTH-001 trial of VET3-TGI (NCT06444815): https://clinicaltrials.gov/study/NCT06444815
- KaliVir: 14 million dollar Series A extension (August 2026): https://kalivir.com/wp-content/uploads/2026/08/KaliVir_pr-08-19-2026_Announces-Closing-of-14-Million-Series-A-Extension-Financing.pdf

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)

---
JSON: https://onco.cc/api/v1/entities/kalivir-immunotherapeutics.json